Endothelin and cardiac arrhythmias: Do endothelin antagonists have a therapeutic potential as antiarrhythmic drugs?

Cardiovascular Research

Volumn 49, Issue 2, 2001, Pages 272-280

  Duru, Firat ^a   Barton, Matthias ^a   Lüscher, Thomas F ^a   Candinas, Reto ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Antiarrhythmic agents; Arrhythmia (mechanisms); Endothelins

Indexed keywords

AMINO ACID; ANTIARRHYTHMIC AGENT; ENDOTHELIN; ENDOTHELIN RECEPTOR ANTAGONIST; HYDROGEN; INOSITOL TRISPHOSPHATE; NITRIC OXIDE; POTASSIUM; SODIUM;

ACIDOSIS; ACTION POTENTIAL; ARRHYTHMOGENESIS; CALCIUM TRANSPORT; CELL DAMAGE; GENETIC TRANSCRIPTION; HEART ARRHYTHMIA; HEART DEPOLARIZATION; HEART VENTRICLE ARRHYTHMIA; POTASSIUM CURRENT; PRIORITY JOURNAL; QT INTERVAL; REVIEW; VASOCONSTRICTION;

ACTION POTENTIALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; ENDOTHELINS; HUMANS; ION CHANNELS; MODELS, CARDIOVASCULAR; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RECEPTORS, ENDOTHELIN;

EID: 0035253797     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0008-6363(00)00263-7     Document Type: Review

References (89)

1. The arrhythmogenic action of endothelin in rats
2. Evidence for direct arrhythmogenic action of endothelin
3. Electrophysiological effects of endothelin-1 on canine myocardial cells
4. Proarrhythmic activity of intracoronary endothelin in dogs: Relation to the site of administration and to changes in regional flow
5. Ventricular tachycardias induced by intracoronary administration of endothelin-1 in dogs
6. Role of endothelin in a rabbit model of acute myocardial infarction: Effects of receptor antagonists
7. Electrophysiological effects of intrapericardial infusion of endothelin-1
8. Mechanism of endothelin-induced malignant ventricular arrhythmias in dogs
9. Increased monophasic action potential dispersion in endothelin-1-induced ventricular arrhythmias
10. Bradycardia increases the arrhythmogenic effect of endothelin
11. Verapamil reduces the arrhythmogenic effect of endothelin
12. A-receptor antagonist, BQ123, on ischemic arrhythmias in anesthetized rats
13. Arrhythmogenic action of endothelin peptides in isolated perfused whole hearts from guinea pigs and rats
14. The endothelin-A antagonist LU 135 252 supresses ischemic ventricular extrasystoles and fibrillation in pigs and prevents hypoxic cellular decoupling
15. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine
16. Characterization of a coronary vasoconstrictor produced by cultured endothelial cells
17. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
18. Constitutive endothelin-1 overexpression promotes smooth muscle cell proliferation via an external autocrine loop
19. Trophic effect of angiotensin II in neonatal rat cardiomyocytes: Role of endothelin-1 and non-myocyte cells
20. A-antagonist
21. A receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice
22. ECE-1: A membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1
23. Organization of the gene encoding the human endothelin-converting enzyme (ECE-1)
24. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis
25. Endothelin in human congestive heart failure
26. The human endothelin family: Three structurally and pharmacologically distinct isopeptides predicted by three separate genes
27. Endothelin antagonists for hypertension and renal disease
28. Characterization and localization of endothelin receptor subtypes in the human atrioventricular conducting system and myocardium
29. B receptors in human vascular smooth muscle
30. A subtype
31. B receptor in endothelial cells. Receptor coupling to nitric oxide synthase
32. Endothelin receptors in cultured adult rat cardiac fibroblasts
33. B in human kidney
34. Possible role of endothelin in endothelial regulation of vascular tone
35. Endothelin receptors in the failing and nonfailing human heart
36. Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium
37. Expression of endothelin-1, endothelin-converting enzyme, and endothelin receptors in chronic heart failure
38. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators
39. The solution structure of a cyclic endothelin antagonist, BQ-123, based on 1 H-1 H and 13C-1H three bond coupling constants
40. BQ-123, cyclo(-D-Trp-D-Asp-Pro-D-Val-Leu), is a non-competitive antagonist of the actions of endothelin-1 in SK-N-MC human neuroblastoma cells
41. A receptor
42. The endothelin-1 receptor antagonist BQ-123 reduces infarct size in a canine model of coronary occlusion and reperfusion
43. A) receptor antagonist, prevents ischemia-reperfusion injury in kidney transplantation
44. Atypical antagonism observed with BQ-123 in human saphenous vein
45. Characterization of the endothelin receptor selective agonist, BQ3020 and antagonists BQ123, FR139317, BQ788, 50235, Ro462005 and bosentan in the heart
46. Lethal ischemia due to intracoronary endothelin in pigs
47. Ischemia-induced and reperfusion-induced arrhythmias differ in their sensitivity to potassium: Implications for mechanisms of initiation and maintenance of ventricular fibrillation
48. Role of endothelin-A receptors in ischemic contracture and reperfusion injury
49. Postischemic antiarrhythmic effects of angiotensin-converting enzyme inhibitors: Role of suppression of endogenous endothelin secretion
50. Modulation of endothelin-1 effects on rat hearts and cardiomyocytes by nitric oxide and 8-bromo cyclic GMP
51. 3 and arrhythmogenic responses during myocardial reperfusion: Evidence for receptor specificity
52. Inhibition of inositol(1,4,5) trisphosphate generation by endothelin-1 during postischemic reperfusion: A novel antiarrhythmic mechanism
53. Investigating the dual nature of endothelin-1: Ischemia or direct arrhythmogenic effect?
54. Ventricular arrhythmias induced by endothelin-1 or by acute ischemia: A comparative analysis using three-dimensional mapping
55. Endothelin and ischaemic arrhythmias - Antiarrhythmic or arrhythmogenic?
56. Preconditioning of coronary artery against vasoconstriction by endothelin-1 and prostaglandin F2α during repeated downregulation of epsilon-protein kinase C
57. Enthelin-1 and myocardial preconditioning
58. Role of endothelin, nitric oxide and l-arginine release in ischemia-reperfusion injury of rat heart
59. Endothelin release during ischemia and reperfusion of isolated perfused rat hearts
60. Circulating and tissue immunoreactivity in advanced atherosclerosis
61. Increased plasma endothelin-1 in the early hours of acute myocardial infarction
62. Contribution of endogenous generation of endothelin-1 to basal vascular tone
63. Systemic endothelin receptor blockade decreases peripheral vascular resistance and blod pressure in humans
64. Human pericardial fluid contains the highest amount of endothelin of all mammalian fluids tested so far
65. Intrapericardial infusion of endothelin-1 induces ventricular arrhythmias in dogs
66. Polar secretion of endothelin-1 by cultured endothelial cells
67. Positive chronotropic effects of endothelin, a novel endothelium-derived vasoconstrictor peptide
68. Endothelin-1-induced vasoconstriction in humans. Reversal by calcium channel blockade but not by nitrovasodilators or endothelium-derived relaxing factor
69. Differential responsiveness of conduit and resistance coronary arteries to endothelin A and B receptor stimulation in anesthetized dogs
70. Endothelins: Molecular biology, biochemistry, pharmacology, physiology, and pathophysiology
71. 2+ transients and contractility in rabbit ventricular myocardium
72. IP3 during myocardial ischemia and its relationship to the development of arrhythmias
73. Suppression of ventricular arrhythmias during ischemia-reperfusion by agents inhibiting Ins(1,4,5)P3 release
74. Arrhythmogenic action of thrombin during myocardial reperfusion via release of inositol 1,4,5-triphosphate
75. Endothelin-1 inhibits the slow component of cardiac delayed rectifier K+ currents via a pertussis toxin-sensitive mechanism
76. Control of ionic permeabilities in normal and ischemic heart
77. Rational basis for use of sodium-hydrogen exchange inhibitors in myocardial ischemia
78. Mechanisms of protection of the ischemic and reperfused myocardium by sodium-hydrogen exchange inhibition
79. Endothelins and endothelin receptor antagonists. Therapeutic considerations for a novel class of cardiovascular drugs
80. Arrhythmogenic effects induced by coronary conversion of pulmonary big endothelin to endothelin: Aggravation of this phenomenon in heritable hyperlipidemia
81. Bosentan, the mixed endothelin A/B receptor antagonist suppresses intrapericardial endothelin-1 induced ventricular arrhythmias
82. SB 209670 inhibits the arrhythmogenic actions of endothelin-1 in the anesthetized dog
83. Effect of non-selective endothelin blockade, TAK-044, on the ischemic cellular injury of rat heart
84. Contractile and arrhythmic effects of endothelin receptor agonists in human heart in vitro: Blockade with SB 209670
85. Autoradiographical localization of binding sites for porcine endothelin-1 in humans, pigs, and rats: Functional relevance in humans
86. Endothelin is a positve inotrop in human and rat heart in vitro
87. Endothelin plasma levels during heart surgery: Influence on pulmonary artery pressure?
88. Circulating endothelin in cardiac operations: Influence of blood pressure and endotoxin